We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Letrozoleis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Letrozole studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2003–2022 with a typical study size of 42 participants.
Based on 8 studies · 2 meta-analyses · 5 RCTs · 846 total participants
Confidence
HighBy outcome
Letrozole has an evidence score of 5/10 — emerging evidence based on 8 indexed studies, including 2 meta-analyses. A potent non-steroidal aromatase inhibitor (Femara) that blocks estrogen synthesis. Approved for hormone-receptor-positive breast cancer, it is also the evidence-backed first-line drug for ovulation induction in PCOS — where a landmark NEJM RCT showed it BEAT clomiphene on live births. Used off-label in men to raise testosterone and lower estradiol, but that estrogen suppression harms bone and lipids, and in growing boys it carries a vertebral-deformity signal. A prescription drug, not a supplement, and NOT a longevity drug. Representative study: PMID 36165742.
The commonly studied dose of Letrozole is Indication-specific and clinician-directed. Ovulation induction: 2.5-7.5 mg once daily for 5 days early in the cycle (typically days 3-7). Breast cancer: 2.5 mg once daily continuously. Off-label male use mirrors 2.5 mg once to a few times weekly (NOT daily) titrated to testosterone/estradiol — a prescription drug, not an approved supplement regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Last reviewed June 2026 · evidence from 8 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Letrozole (Femara) — non-steroidal aromatase inhibitor
A potent non-steroidal aromatase inhibitor (Femara) that blocks estrogen synthesis. Approved for hormone-receptor-positive breast cancer, it is also the evidence-backed first-line drug for ovulation induction in PCOS — where a landmark NEJM RCT showed it BEAT clomiphene on live births. Used off-label in men to raise testosterone and lower estradiol, but that estrogen suppression harms bone and lipids, and in growing boys it carries a vertebral-deformity signal. A prescription drug, not a supplement, and NOT a longevity drug.
Letrozole has guideline-grade evidence for female ovulation induction — a landmark NEJM RCT and high-certainty Cochrane reviews show it beats clomiphene on live births in PCOS — plus an approved breast-cancer role. But the off-label male use (raising testosterone by suppressing estradiol) showed NO somatic/psychological benefit in a placebo-controlled RCT and carries real bone and lipid costs, and in growing boys it raised vertebral-deformity prevalence (45% vs 0% on placebo). Strong where it is strong, genuinely risky off-label, and NOT a longevity agent — so it stays emerging overall.
Letrozole is a third-generation non-steroidal aromatase inhibitor (AI) that reversibly blocks the aromatase (CYP19A1) enzyme, the step that converts androgens to estrogens. By suppressing estradiol it serves two very different clinical purposes.
Its approved use is in postmenopausal hormone-receptor-positive breast cancer, where lowering circulating estrogen starves estrogen-dependent tumors.
Its strongest fertility evidence is in ovulation induction: in women with polycystic ovary syndrome (PCOS), lowering estrogen transiently releases the hypothalamic-pituitary axis from estrogen feedback, raising FSH and recruiting a dominant follicle.
The landmark NICHD/Legro NEJM trial (750 women) randomized letrozole versus clomiphene and found letrozole produced more cumulative live births (27.5% vs 19.1%) and higher ovulation rates, with similar miscarriage and a lower multiple-pregnancy tendency.
Cochrane systematic reviews (2018, 2022) pooled dozens of RCTs and reached high-certainty conclusions that letrozole improves live-birth and pregnancy rates over clomiphene in anovulatory PCOS, with similar OHSS rates — which is why guidelines now place letrozole first-line for PCOS ovulation induction even though that indication is off-label in many regions.
In men, the same mechanism (lower estradiol, less negative feedback) raises LH, FSH, and testosterone; small RCTs in obese hypogonadal men confirm letrozole roughly doubles testosterone and halves estradiol.
The honest male-use caveat is large: a double-blind RCT in obese men found that despite a marked testosterone rise, low-dose letrozole produced NO somatic or psychological benefit, and estrogen is essential for male bone and lipid health, so chronic aromatase inhibition risks bone loss and adverse lipids.
In growing boys, letrozole delays bone-age advancement and increases predicted adult height in short stature / constitutional delay — but the strongest counter-evidence is a bone study showing mild vertebral-body deformities in 45% of letrozole-treated boys versus 0% on placebo, a mandatory honesty limit when AIs are used during growth.
The score reflects genuinely strong, guideline-grade evidence for female ovulation induction (better than clomiphene) and an established oncology role, set against off-label male use whose benefit is unproven and whose estrogen suppression carries real bone/lipid costs.
Letrozole is a prescription drug, not a supplement, and there is no longevity rationale — it is not and should not be tagged as a longevity drug.
Letrozole reversibly blocks the aromatase enzyme that converts androgens (testosterone, androstenedione) into estrogens, lowering circulating estradiol throughout the body.
Lower estradiol means less negative feedback on the hypothalamus and pituitary, which raises FSH and LH. In women this recruits a dominant follicle for ovulation; in men it drives the testes to make more testosterone.
In hormone-receptor-positive breast cancer, low estrogen starves estrogen-dependent tumors. In growing children, estrogen normally fuses growth plates, so suppressing it delays bone-age advancement and can increase predicted adult height.
How Letrozole works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Indication-specific and clinician-directed. Ovulation induction: 2.5-7.5 mg once daily for 5 days early in the cycle (typically days 3-7). Breast cancer: 2.5 mg once daily continuously. Off-label male use mirrors 2.5 mg once to a few times weekly (NOT daily) titrated to testosterone/estradiol — a prescription drug, not an approved supplement regimen.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral letrozole 2.5 mg tablet (Femara / generic) | Recommended |
| 💊Anastrozole (another non-steroidal aromatase inhibitor) | Alternative |
| 💊Clomiphene citrate (the SERM letrozole outperforms for PCOS ovulation induction) | Alternative |
Letrozole is the non-steroidal AI with the strongest ovulation-induction evidence; anastrozole is the closest class alternative.
Compare Letrozole vs Anastrozole →Minimum: 1 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Ovulation induction is a 5-day course early in the cycle; breast-cancer use is continuous daily; off-label male use is intermittent and titrated to hormone levels by a clinician.
Dose-response data unavailable. The current published research for Letrozole does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
First-line for PCOS ovulation induction — a landmark NEJM RCT and Cochrane reviews show higher live-birth and ovulation rates than clomiphene.
In obese hypogonadal men, letrozole roughly doubles testosterone and halves estradiol by releasing estrogen feedback — but a placebo-controlled RCT found no somatic or psychological benefit.
Estrogen is essential for male and skeletal health; chronic aromatase inhibition risks bone loss, adverse lipids, and (in growing boys) vertebral deformities.
Approved for hormone-receptor-positive breast cancer in postmenopausal women, where estrogen deprivation slows estrogen-dependent tumor growth.
This is the strongest-evidence use — first-line ovulation induction, beating clomiphene on live births. Use under a fertility clinician; stop once pregnant.
It does raise testosterone and lower estradiol, but a placebo-controlled RCT showed no symptomatic benefit, and estrogen suppression harms bone and lipids. Not a validated TRT alternative; monitor estradiol, bone density, and lipids if used at all.
Investigational; can increase predicted height but carries a vertebral-deformity signal. Only under pediatric endocrinology with spine monitoring.
Teratogenic — must not be taken during an established pregnancy. Ovulation-induction courses are given before conception and stopped once pregnancy is confirmed.
Overlapping or opposing effects on the estrogen axis; tamoxifen can reduce letrozole plasma levels when co-administered.
Estrogen supplementation works directly against letrozole's mechanism and would blunt its effect.
Tip: A direct consequence of low estrogen; usually tolerable and reversible on stopping.
Tip: Reported more with letrozole than clomiphene in the ovulation-induction trial; usually transient.
Tip: Estrogen-deprivation joint symptoms, well known from long-term breast-cancer use.
Tip: Estrogen is needed for bone and lipid health; monitor bone density and lipids with prolonged or off-label male use.
Tip: Mild vertebral deformities occurred in 45% of letrozole-treated boys vs 0% on placebo; if used during growth, follow vertebral morphology.
Timing is flexible for Letrozole — consistent daily use matters more than the time of day. Taken orally with or without food.
Letrozole should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are hot flashes, fatigue / dizziness, arthralgia / musculoskeletal aches. Use caution if any of these apply to you: Pregnancy (teratogenic risk) — used to induce ovulation, but stopped once pregnancy occurs; Premenopausal women for breast-cancer indication without ovarian suppression; Hypersensitivity to letrozole.
Often stacked off-label to control estradiol, but combining androgens with aromatase inhibition can drive estradiol too low and worsen bone/lipid effects; not a validated protocol.